Ocular Therapeutix (OCUL) Trading 0% Higher

Ocular Therapeutix Inc (NASDAQ:OCUL) shares traded up 0% during trading on Friday . The stock traded as high as $6.36 and last traded at $6.22. 12,065 shares changed hands during trading, a decline of 96% from the average session volume of 340,206 shares. The stock had previously closed at $6.22.

Several research analysts have recently commented on the company. ValuEngine upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright set a $10.00 target price on Ocular Therapeutix and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald set a $22.00 target price on Ocular Therapeutix and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Zacks Investment Research downgraded Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, BidaskClub downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Ocular Therapeutix currently has a consensus rating of “Hold” and an average price target of $12.81.

The firm has a market capitalization of $227.69 million, a price-to-earnings ratio of -2.83 and a beta of 1.11. The company has a quick ratio of 4.89, a current ratio of 4.92 and a debt-to-equity ratio of 0.21.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.37). The business had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.35 million. Ocular Therapeutix had a negative return on equity of 143.32% and a negative net margin of 2,814.72%. equities research analysts anticipate that Ocular Therapeutix Inc will post -1.55 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in OCUL. BlackRock Inc. lifted its holdings in Ocular Therapeutix by 0.8% during the 4th quarter. BlackRock Inc. now owns 1,418,577 shares of the biopharmaceutical company’s stock worth $6,312,000 after purchasing an additional 11,293 shares during the last quarter. Deutsche Bank AG lifted its holdings in Ocular Therapeutix by 148.7% during the 4th quarter. Deutsche Bank AG now owns 50,065 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 29,938 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Ocular Therapeutix by 39.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 53,570 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 15,100 shares during the last quarter. Summer Road LLC acquired a new stake in Ocular Therapeutix during the 1st quarter worth approximately $19,709,000. Finally, Northern Trust Corp lifted its holdings in Ocular Therapeutix by 24.1% during the 1st quarter. Northern Trust Corp now owns 324,526 shares of the biopharmaceutical company’s stock worth $2,112,000 after purchasing an additional 62,993 shares during the last quarter. 57.75% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Recommended Story: Should you buy a closed-end mutual fund?

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply